Published in TZ Latest News
13 January, 2017 by The TZ Newswire Staff
Can Biotechs Recover From Trump’s Strong Condemnation?
From Zacks: The pharma and biotech industry is a victim of concerns over increased regulatory scrutiny on high drug prices over the past two years. The worries cooled down after Trump’s victory, and gave biotech stocks a shot in the arm.